ICD-10 Coding for Mycophenolate Orders
The appropriate ICD-10 code for ordering mycophenolate depends entirely on the underlying medical condition being treated—there is no single universal code for this medication. You must use the diagnosis code that corresponds to the specific disease indication, such as organ transplant status codes (Z94.x series) or autoimmune disease codes.
Primary FDA-Approved Indications
Based on FDA labeling, mycophenolate is approved for prevention of organ rejection in kidney, heart, and liver transplant recipients 1. For these patients, use the appropriate transplant status codes:
Solid Organ Transplant Status Codes:
- Z94.0 - Kidney transplant status
- Z94.1 - Heart transplant status
- Z94.4 - Liver transplant status
These codes should be used when ordering mycophenolate for transplant recipients receiving the medication as maintenance immunosuppression 2, 1.
Off-Label Autoimmune Disease Indications
While not FDA-approved for these conditions, mycophenolate is widely used and guideline-recommended for various autoimmune diseases:
Lupus Nephritis
- N08.5 - Glomerular disorders in systemic connective tissue disorders
- M32.14 - Glomerular disease in systemic lupus erythematosus
Mycophenolate is a first-line agent for both induction and maintenance therapy in lupus nephritis 3, 4. The 2024 KDIGO guidelines strongly recommend mycophenolate as the preferred maintenance agent after initial therapy (Grade 1B) 4.
Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease (SARD-ILD)
- J84.89 - Other specified interstitial pulmonary diseases
- Plus the underlying autoimmune disease code (e.g., M34.81 for systemic sclerosis with lung involvement)
For SARD-ILD, mycophenolate is conditionally recommended as the preferred first-line therapy across multiple conditions including systemic sclerosis, rheumatoid arthritis, Sjögren's disease, and mixed connective tissue disease 5.
Autoimmune Hepatitis
- K75.4 - Autoimmune hepatitis
Mycophenolate can be used as an alternative to azathioprine in patients with TPMT deficiency or azathioprine intolerance 6. Recent evidence suggests MMF may have superior efficacy for achieving complete biochemical response compared to azathioprine 7.
Atopic Dermatitis (Severe, Refractory)
- L20.9 - Atopic dermatitis, unspecified (or more specific L20.8x codes)
For refractory moderate-to-severe atopic dermatitis, mycophenolate is conditionally recommended with proper monitoring 8.
Important Coding Considerations
Do not use adverse drug event T-codes (T36-T50 series) when ordering mycophenolate therapeutically. These codes are only for documenting adverse effects or poisoning from medications 9, 10, 11. Using T-codes inappropriately may flag the order as an adverse event rather than legitimate therapy.
The diagnosis code must reflect the active medical condition requiring immunosuppression, not the medication itself. Insurance authorization and pharmacy processing depend on appropriate diagnosis coding that matches approved or accepted indications.
Monitoring Requirements
Regardless of the indication, when ordering mycophenolate, ensure appropriate monitoring is in place 12, 5:
- CBC with differential at baseline, 2-3 weeks after starting, 2-3 weeks after dose changes, then every 3 months
- Comprehensive metabolic panel (same schedule as CBC)
- Pregnancy testing in women of childbearing potential (black box warning for teratogenicity) 1
- Full body skin examination annually (increased malignancy risk)
For GI adverse effects including diarrhea, interruption or dose reduction is recommended (Grade 1B) 12.